Sonnet BioTherapeutics Announces Updated Clinical Data for SON-1010

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN) has announced updated data from its Phase 1 clinical trials of SON-1010. The trials have enrolled 61 subjects to date, with patients receiving up to 25 cycles of SON-1010 monotherapy and 10 cycles when combined with atezolizumab (Tecentriq®), without dose-limiting toxicity.

Studies demonstrate a roughly 10-fold extended half-life for SON-1010 compared to rhIL-12, leading to prolonged IFNγ responses and no cytokine release syndrome. Clinical benefit was observed in 35% of evaluable patients with advanced solid tumors four months post-initiation.

The trials are now increasing the target dose. SB101 focuses on advanced solid tumors, while SB221 includes a combination with atezolizumab for platinum-resistant ovarian cancer. Safety profiles show mild, transient adverse events, and 60% of patients showed stable disease at follow-up.